Second phase III study of BUPI for pain management in oral mucositis in cancer patients

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 12 Aug 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupivacaine (Primary)
Indications Pain
Focus Therapeutic Use
Sponsors Moberg Pharma

Most Recent Events

08 Aug 2017 According to a Moberg Pharma media release, during the second quarter the company provided input on this study application for BUPI to their partner Cadila Pharmaceuticals.Submission preparations by Cadila are in the final stages.
28 Mar 2016 New trial record

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight